"Our research shows that incorporating a line guard into our infection-prevention protocols can deliver meaningful benefits for children requiring central line access." ...
Covalon Announces Publication of Impactful VALGuard® Line Guard Clinical Study Demonstrating Significant Reduction in Central Line-Associated Blood Stream Infections (CLABSIs) Peer-reviewed study ...
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced the publication of results from a peer-reviewed clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback